Medical Week Daily

Medical news today: Wednesday, November 18, 2026

White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators

Get tomorrow's issue in your inbox.

  1. 01

    UK watchdog bans Voy's at-home testosterone test ads as misleading

    Source: BBC

    The UK Advertising Standards Authority banned five Voy adverts, three posters and two paid Facebook ads, for its at-home testosterone blood tests, saying they misleadingly linked common symptoms such as irritability and fatigue to low testosterone, the BBC reports. Voy said it had withdrawn the ads and would not run them again; the NHS says falling testosterone with age is unlikely to cause problems in itself.

    Why it mattersDirect-to-consumer tests often lead to paid follow-up treatments. Tiredness or low mood has many causes, so see a doctor, who can order tests that are actually needed, before paying for a home kit. More on Infectious disease →

  2. 02

    FDA launches a programme to share its approval reviews with regulators abroad

    Source: US FDA

    The FDA announced the Global Reliance Disclosure Program, which lets drugmakers obtain minimally redacted FDA approval packages and share them with foreign regulators so those agencies can rely on the FDA's review instead of repeating it. It began on 30 October with PEPFAR tentative approvals and the FDA intends to extend it to all novel drugs and biologics in January 2027.

    Why it mattersPatients in many countries wait months or years after a US approval for their own regulator's review. If other regulators use these packages, new medicines could reach markets such as India sooner; each country still makes its own decision. More on Approvals & regulatory →

    Market news · Not investment advice

  3. 03

    FDA approves Lembaz, the first drug shown to help babies with infantile Niemann-Pick type C live longer

    Source: US FDA

    The FDA approved Lembaz (adrabetadex) injection, which it says is the first treatment shown to help people with a severe form of Niemann-Pick disease type C, a rare inherited disorder, live longer.

    Why it mattersRare-disease drugs are often among the most expensive medicines in the world. Families affected by NPC should ask their specialist about access routes, such as clinical programmes or patient-support schemes, rather than assuming the drug is out of reach. More on Approvals & regulatory →

  4. 04

    US loses measles elimination status after two years of large outbreaks

    Source: STAT

    A committee of the Pan American Health Organization said measles is no longer considered eliminated in the United States, a status the country had held since 2000, STAT reports. The decision recognises transmission that has already occurred during the far larger outbreaks of the past two years.

    Why it mattersMeasles can mean hospital stays and weeks off work or school, and vaccination costs far less than treatment. Check your family's vaccination records with your doctor, especially before international travel. More on Infectious disease →

  5. 05

    Bengaluru-built AI tool for spotting blinding eye disease in premature babies wins CDSCO approval

    Source: The Times of India

    An AI tool developed by Bengaluru's Remidio with KIDROP, a Karnataka government and Narayana Nethralaya partnership, received approval from India's drug regulator CDSCO last week, The Times of India reports. It analyses retinal images of premature babies at the bedside and flags suspected retinopathy of prematurity (ROP) for specialist review.

    Why it mattersROP can cause blindness, and specialists are scarce outside big cities. Cheaper bedside screening could mean fewer costly trips for families; parents of premature babies should still ask their neonatal unit when the baby's eye check is due. More on Approvals & regulatory →

  6. 06

    EMA adds mRNA flu vaccines to its 2026/27 strain recommendations

    Source: European Medicines Agency

    EMA updated its EU recommendations for 2026/27 seasonal flu vaccine strains on 17 November to include a recommendation for mRNA (nucleic acid) influenza vaccines. The recommended strains for cell-based and nucleic acid vaccines are an A/Missouri/11/2025 (H1N1)pdm09-like virus, an A/Darwin/1415/2025 (H3N2)-like virus and a B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus.

    Why it mattersThe yearly strain update is why last year's flu shot is not enough. A flu shot costs far less than a week of lost pay or a hospital visit; see our flu guide for who should get one. More on Approvals & regulatory →

  7. 07

    Tobacco firms test flavoured nicotine tablets, alarming health advocates

    Source: STAT (The Examination)

    Philip Morris International has introduced Zyn Melts mint nicotine tablets in the UK and Switzerland, and Japan Tobacco International launched a similar product, Perlz, in the UK in May, STAT reports from reporting by The Examination. Public health advocates worry the discreet, sweet-flavoured tablets appeal to children and teens.

    Why it mattersNicotine dependence is a lasting expense as well as a health risk. Parents should know these products can look like mints; adults trying to quit should ask a doctor about proven quit aids, many of them low-cost.

  8. 08

    FDA classes Cardinal Health kits with recalled BD Alaris infusion sets as its most serious recall

    Source: US FDA (MedWatch)

    The FDA updated its early alert on 16 November to classify as Class I, the most serious type, Cardinal Health's correction of Presource procedure kits containing recalled BD Alaris pump infusion sets. The FDA says the affected sets can cause under- or over-infusion or failure to infuse; Cardinal has told customers to quarantine the kits and remove and discard the recalled sets. As of 19 August, BD had reported no serious injuries or deaths linked to the issue.

    Why it mattersThis mainly concerns hospitals, not patients at home. If you or a family member are having infusion treatment, it is reasonable to ask the care team whether their pumps and kits have been checked against current recalls. More on Approvals & regulatory →

  9. 09

    White House withdraws Heidi Overton's nomination to lead the FDA

    Source: MedPage Today (AP)

    The White House pulled the nomination of physician Heidi Overton as FDA commissioner amid signs she lacked the votes for Senate confirmation, the Associated Press reports via MedPage Today. She faced bipartisan questions over her support for breaking up combination vaccines such as MMR; the FDA remains under an acting commissioner and has lost about 20% of its staff since the administration took office, the report says.

    Why it mattersFDA leadership and staffing affect how quickly new medicines, including cheaper generics and biosimilars, reach the market. Prolonged uncertainty at the agency can slow approvals that eventually lower what patients pay. More on Approvals & regulatory →

  10. 10

    FDA grants accelerated approval to neladalkib for previously treated ALK-positive lung cancer

    Source: MedPage Today

    The FDA granted accelerated approval to GSK's neladalkib (Nelkarmi) for advanced ALK-positive non-small cell lung cancer after alectinib or at least two prior ALK inhibitors plus chemotherapy, MedPage Today reports. In the ALKOVE-1 trial, 49% of patients previously given only alectinib and 32% of more heavily treated patients responded; raised liver enzymes were the most common side effect.

    Why it mattersA seventh drug in this class adds competition, which over time can help on price, but accelerated approval means confirmatory evidence is still to come. Patients should weigh benefits, side effects and cost with their oncologist. More on Approvals & regulatory →

New here? How to read this digest
Each story links to its original source. "Why it matters" explains what it means for you in plain language. This is news, not medical advice: talk to your doctor about your own care. Browse all topics or the archive.

More recent digests

Free daily email

The day's approvals, safety signals and trials, in five minutes.

Join the list with just your email. You can also follow the RSS feed.

Free, one field, no spam. We only use your address to send Medical Week Daily and never sell it. Ask to be removed any time via the contact page. See the privacy note.

For information and education only. Not medical advice. Medical Week Daily summarizes published health news in plain language for general readers. It does not replace advice from your doctor, product labeling or regulatory documents. Always consult a qualified healthcare professional about your own care, and check the original source. Full medical disclaimer